Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer Kristin N.

Slides:

Advertisements

Similar presentations

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Advertisements

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Leptomeningeal Disease

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Jasmin JO and David Schiff

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report Kazutaka Fujita, MD, Yuko.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib Naoki Omachi, MD, Shigeki.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Treatment of Cardiac Angiosarcoma with Radiation and Docetaxel: A Case Report with Partial Response and Prolonged Stable Disease Derek Suderman, MD,

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer Josette Biya, MD, Caroline Caramella, MD, Colin.

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Bilateral Patellar Metastases from Non-small Cell Lung Cancer

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Bilateral Subdural Hematoma Associated with Central Nervous System Metastases from Lung Cancer Akito Hata, MD, Shiro Fujita, MD, PhD, Nobuyuki Katakami,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Respiratory dynamic magnetic resonance imaging for determining aortic invasion of thoracic neoplasms Yoo Jin Hong, MD, Jin Hur, MD, Hye-Jeong Lee, MD,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions Samuel G. Armato, PhD, Anna K. Nowak, MD, PhD,

Mitotic Inhibitors Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

An IRIS to Remember The American Journal of Medicine

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Phase I Study of Lenalidomide in Solid Tumors

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Marianna Koczywas, MD, Mihaela C. Cristea, MD

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Metastatic Lung Cancer to the Pancreas

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Complete and Durable Response of Choroid Metastasis from Non-small Cell Lung Cancer with Systemic Bevacizumab and Chemotherapy Ben George, MD, William.

David Garfield, MD Journal of Thoracic Oncology

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Tatsuya.

Who should decide margin length in pulmonary excision of lung cancer?

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing.

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

A Review of First-Line Treatment for Small-cell Lung Cancer

Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report Katarzyna Dziadziuszko, MD, Edyta Szurowska, MD, PhD, Joanna.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer Kristin N. Arreola, MD, James Ying, BSE, Randall Hughes, MD, David E. Gerber, MD, D.W. Nathan Kim, MD, PhD Journal of Thoracic Oncology Volume 9, Issue 8, Pages e60-e61 (August 2014) DOI: 10.1097/JTO.0000000000000172 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Sagittal view of A) T1 post contrast magnetic resonance imaging (MRI) of thoracic spine and B) T1 non-contrasted MRI at the time of initial presentation. A discrete enhancing lesion is noted at the level of fourth thoracic spine concerning for intramedullary spinal cord metastases (dashed circle) and extensive heterogeneous signal (bold arrows) concerning for blood products/hemorrhage surrounding the lesion are noted. Sagittal view of C) T1 post contrast MRI and D) T1 non-contrasted MRI, of thoracic spine approximately 2 months after completion of radiation therapy at similar plane to figure 1A image. This demonstrates reduction in size of the intramedullary metastases (dashed circle) and significant reduction in hemorrhage and mass effect from the tumor. No other new lesions were detected. Journal of Thoracic Oncology 2014 9, e60-e61DOI: (10.1097/JTO.0000000000000172) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions